Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.

ABSTRACT:

SUBMITTER: McCarthy JS 

PROVIDER: S-EPMC8612936 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature